中国循环杂志
中國循環雜誌
중국순배잡지
CHINESE CIRCULATION JOURNAL
2014年
9期
702-705
,共4页
西地那非%高原地区%先天性心脏病%重度肺动脉高压
西地那非%高原地區%先天性心髒病%重度肺動脈高壓
서지나비%고원지구%선천성심장병%중도폐동맥고압
Sildenaifl%Plateau%Congenital heart disease%Severe pulmonary hypertension
目的：探讨西地那非治疗高原地区先天性心脏病合并重度肺动脉高压的临床疗效和安全性。<br> 方法：选择2010-01至2013-10连续转入重症监护病房的先天性心脏病合并重度肺动脉高压患儿50例，随机分为研究组（n=25例）和对照组（n=25例）。对照组给予常规方法治疗，研究组在常规治疗基础上给予口服西地那非治疗，记录治疗前后血流动力学改变、血气、血常规和血生化指标变化。<br> 结果：治疗后研究组患儿肺动脉收缩压的下降程度、动脉血氧分压、左心室心输出量及心脏指数、氧合指数的上升程度均明显优于采用常规治疗的对照组（P<0.05），差异有统计学意义。研究组患儿平均体动脉压、血常规、血生化指标较治疗前均无明显变化（P>0.05），差异无统计学意义，且未发现明显不良反应。<br> 结论：西地那非能有效降低高原地区先天性心脏病合并重度肺动脉高压患儿的肺动脉压力，改善患者的心功能，且应用西地那非无不良反应，初步安全性评估良好。
目的：探討西地那非治療高原地區先天性心髒病閤併重度肺動脈高壓的臨床療效和安全性。<br> 方法：選擇2010-01至2013-10連續轉入重癥鑑護病房的先天性心髒病閤併重度肺動脈高壓患兒50例，隨機分為研究組（n=25例）和對照組（n=25例）。對照組給予常規方法治療，研究組在常規治療基礎上給予口服西地那非治療，記錄治療前後血流動力學改變、血氣、血常規和血生化指標變化。<br> 結果：治療後研究組患兒肺動脈收縮壓的下降程度、動脈血氧分壓、左心室心輸齣量及心髒指數、氧閤指數的上升程度均明顯優于採用常規治療的對照組（P<0.05），差異有統計學意義。研究組患兒平均體動脈壓、血常規、血生化指標較治療前均無明顯變化（P>0.05），差異無統計學意義，且未髮現明顯不良反應。<br> 結論：西地那非能有效降低高原地區先天性心髒病閤併重度肺動脈高壓患兒的肺動脈壓力，改善患者的心功能，且應用西地那非無不良反應，初步安全性評估良好。
목적：탐토서지나비치료고원지구선천성심장병합병중도폐동맥고압적림상료효화안전성。<br> 방법：선택2010-01지2013-10련속전입중증감호병방적선천성심장병합병중도폐동맥고압환인50례，수궤분위연구조（n=25례）화대조조（n=25례）。대조조급여상규방법치료，연구조재상규치료기출상급여구복서지나비치료，기록치료전후혈류동역학개변、혈기、혈상규화혈생화지표변화。<br> 결과：치료후연구조환인폐동맥수축압적하강정도、동맥혈양분압、좌심실심수출량급심장지수、양합지수적상승정도균명현우우채용상규치료적대조조（P<0.05），차이유통계학의의。연구조환인평균체동맥압、혈상규、혈생화지표교치료전균무명현변화（P>0.05），차이무통계학의의，차미발현명현불량반응。<br> 결론：서지나비능유효강저고원지구선천성심장병합병중도폐동맥고압환인적폐동맥압력，개선환자적심공능，차응용서지나비무불량반응，초보안전성평고량호。
Objective: To explore the efifcacy and safety of sildenaifl for treating the patients of congenital heart disease (CHD) with severe pulmonary hypertension in plateau area. <br> Methods: A total of 50 CHD patients combining severe pulmonary hypertension treated in our hospital from 2010-01 to 2013-10 were studied. The patients were randomly divided into 2 groups, n=25 in each group. Control group, the patients received conventional treatment and Sildenaifl group, based on conventional treatment, the patients received additional sildenaifl medication. The hemodynamic, blood gas, routine and biochemistry were recorded and compared between 2 groups. <br> Results: Compared with Control group, Sildenaifl group had more reduction of pulmonary artery pressure, increased arterial pressure of oxygen, left ventricular output, cardiac index and oxygenation index, all P<0.05. The patients’ arterial pressure, blood routine and biochemistry were similar between 2 groups, P>0.05. There was no obvious adverse reaction observed in Sildenaifl group. <br> Conclusion: Based on conventional treatment, Sildenafil may effectively reduce the pulmonary artery pressure in CHD patients combining pulmonary hypertension in plateau area, it improving the cardiac function without adverse reaction.
